Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...
Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...
Hosted on MSN3h
William Blair Initiates Coverage of Altimmune (ALT) with Market Perform RecommendationFintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform ...
Earnings per share (EPS) was mostly in line with analyst estimates. Looking ahead, revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 20% growth forecast for the ...
13h
Piper Sandler analyst Yasmeen Rahimi initiated coverage on Avalo Therapeutics, Inc. AVTX with an Overweight rating and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback